GRF(1-29) raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-02 and is reviewed periodically as new material appears.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Assessed by visual inspection under ordinary light |
| Primary analytical method | Reversed-phase liquid chromatography | Purity estimated from peak area at 214 nm |
| Confirmatory method | Mass spectrometry | Observed mass compared with calculated value |
| Powder storage temperature | Minus 20 degrees Celsius | Minus 80 for extended archival periods |
| Solution stability | Hours to days at 2 to 8 degrees Celsius | Influenced by pH, buffer, and concentration |
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Analysis of the insect os-d-like gene family. J Chem Ecol. 2004; 30: 889-911. 41. Forêt S, Wanner KW, Maleszka R. Chemosensory proteins in the honeybee: Insights from the annotated genome, comparative analysis and expression profiling. Insect Biochem Mol Biol. 2007; 37: 19-28. 42. Ozaki K, Utoguchi A, Yamada A, Yoshikawa H. Identification and genomic structure of chemosensory proteins (CSP) and odorant binding proteins (OBP) genes expressed in foreleg tarsi of the swallowtail butterfly Papilio xuthus. Insect Biochem Mol Biol. 2008; 38: 969-76. 43. Liu GX, Arnaud P, Offmann B, Picimbon JF. Genotyping and bio-sensing chemosensory proteins in insects. Sensors 2017; 17: 1801. 44. Mei T, Fu WB, Li B, He ZB, Chen B. Comparative genomics of chemosensory protein genes (CSPs) in twenty-two species (Diptera: Culicidae): identification, characterization, and evolution. PLoS ONE 2018; 13: e0190412. 45. Kulmuni J, Wurm Y, Pamilo P. Comparative genomics and chemosensory protein genes reveals rapid evolution and positive selection in ant-specific duplicates. Heredity 2013; 110: 538-547. 46. Pikielny CW, Hasan G, Rouyer F, Rosbach M. Members of a family of Drosophila putative odorant-binding proteins are expressed in different subsets of olfactory hairs. Neuron (1994) 12: 35-49. 47. McKenna MP, Hekmat-Scafe DS, Gaines P, Carlson JR. Putative Drosophila pheromone-binding-proteins expressed in a subregion of the olfactory system. J Biol Chem (1994) 269: 16340-16347. 48. Robertson HM, Martos R, Sears CR, Todres EZ, Walden KK, Nardi JB.
took over mass production, but without an exclusive license, as the patent was transferred to the Medical Research Council to prevent exploitation. In the summer of 1923 Macleod resumed other research. He took interest in teleost fish, which have separate regions of islet and acinar tissue in their pancreas. Working at the Marine Biological Station in St. Andrews, New Brunswick, he made extracts from each of those parts separately and proved that insulin is derived from the insular and not the acinar tissue of the pancreas. Meanwhile, Banting remained in Toronto and relationships soon deteriorated again because of conflicting press accounts. Banting eventually started to claim that he deserved all the credit and that Macleod had only hindered him the whole time and had made no contribution other than to leave the keys to the laboratory when he went on vacation. MacLeod wrote a report on the discovery in 1922 to explain his side of the story, but otherwise refrained from active involvement in controversy about credit. Banting hated him passionately, and the two never spoke again. When Macleod left the University of Toronto in 1928, Banting harbored such enmity that he refused to attend the farewell dinner for Macleod.
The 1st Brigade was among the federal forces that left Baltimore by midnight the same day and three days later, the 2nd Brigade went into an assembly area at Bolling Air Force Base, where they eventually departed back to Fort Bragg sometime later.
While most cephalopods can move by jet propulsion, this is a very energy-consuming way to travel compared to the tail propulsion used by fish. The efficiency of a propeller-driven waterjet (i.e. Froude efficiency) is greater than a rocket. The relative efficiency of jet propulsion decreases further as animal size increases; paralarvae are far more efficient than juvenile and adult individuals. Since the Paleozoic era, as competition with fish produced an environment where efficient motion was crucial to survival, jet propulsion has taken a back role, with fins and tentacles used to maintain a steady velocity. Whilst jet propulsion is never the sole mode of locomotion, the stop-start motion provided by the jets continues to be useful for providing bursts of high speed – not least when capturing prey or avoiding predators. Indeed, it makes cephalopods the fastest marine invertebrates, and they can out-accelerate most fish. The jet is supplemented with fin motion; in the squid, the fins flap each time that a jet is released, amplifying the thrust; they are then extended between jets (presumably to avoid sinking). Oxygenated water is taken into the mantle cavity to the gills and through muscular contraction of this cavity, the spent water is expelled through the hyponome, created by a fold in the mantle. The size difference between the posterior and anterior ends of this organ control the speed of the jet the organism can produce. The velocity of the organism can be accurately predicted for a given mass and morphology of animal.
Sources: en.wikipedia.org
The presence of gastrin stimulates parietal cells of the stomach to secrete hydrochloric acid (HCl)/gastric acid. This is done both directly on the parietal cell and indirectly via binding onto CCK2/gastrin receptors on ECL cells in the stomach, which respond by releasing histamine, which in turn acts in a paracrine manner on parietal cells stimulating them to secrete H+ ions. This is the major stimulus for acid secretion by parietal cells. Along with the above-mentioned function, gastrin has been shown to have additional functions as well:
=== Synthesis === The chemical synthesis of LSD has been described. It is commonly synthesized by reacting diethylamine with an activated form of lysergic acid. Activating reagents include phosphoryl chloride and peptide coupling reagents. Lysergic acid is made by alkaline hydrolysis of lysergamides like ergotamine, a substance usually derived from the ergot fungus on agar plate. Lysergic acid can also be produced synthetically, although these processes are not used in clandestine manufacture due to their low yields and high complexity. Albert Hofmann synthesized LSD in the following manner: (1) hydrazinolysis of ergotamine into D- and L-isolysergic acid hydrazide, (2) separation of the enantiomers with di-(p-toluyl)-D-tartaric acid to get D-isolysergic acid hydrazide, (3) enantiomerization into D-lysergic acid hydrazide, (4) substitution with HNO2 to D-lysergic acid azide and (5) finally substitution with diethylamine to form D-lysergic acid diethylamide. The precursor for LSD, lysergic acid, has been produced by GMO baker's yeast.
Initial experiments on the reaction of carbon monoxide with metals were carried out by Justus von Liebig in 1834. By passing carbon monoxide over molten potassium he prepared a substance having the empirical formula KCO, which he called Kohlenoxidkalium. As demonstrated later, the compound was not a carbonyl, but the potassium salt of benzenehexol (K6C6O6) and the potassium salt of acetylenediol (K2C2O2).
Sources: en.wikipedia.org
==== Dry spinning ==== Dry-spinning, an ancient spinning method, dissolves polymers in solvents, unlike melt-spinning. Polymer solutions are extruded through a spinneret and then passed through a heating column where the solvent evaporates, leaving dry fibers. Highly volatile solvents are needed for this process. Steam or hot air is utilized to solidify fibers and remove solvent. This technique suits polymers prone to thermal degradation and those unable to form viscous melts, offering specific surface characteristics. Traditional dry-spun polymers include acetate, triacetate, acrylics, modacrylics, aramid, and spandex fibers. Besides being complex and costly due to recovery processes and mass transfer mechanisms during solvent evaporation, dry-spinning provides fibers with unique properties.
Trails has seen several spin-offs and works in other types of media, including manga, audio dramas, and anime. Ys vs. Trails in the Sky is a crossover fighting game featuring characters from Trails and Falcom's Ys series. It was released exclusively in Japan in July 2010 but received an English fan translation patch in October 2021. The Legend of Nayuta: Boundless Trails was released in Japan in July 2012 and worldwide in 2023. It does not take place within Zemuria and also differs from the rest of the series by being an action role-playing game. The Legend of Heroes: Trails at Sunrise is a Japanese-only gacha game developed by UserJoy Technology. It was first released in 2016 as a browser game before being ported to other platforms. An original video animation adaptation of Trails in the Sky SC was produced by Kinema Citrus. Part one was released in November 2011 while the second was released in February 2012. They were licensed by Sentai Filmworks for release in North America that same year. A 12-episode anime series produced by Tatsunoko Production, The Legend of Heroes: Trails of Cold Steel – Northern War, aired in early 2023. A mobile game based on the anime was released in Japan in December 2023 and worldwide in May 2024. Several manga adaptations of games in the series have been released. Trails in the Sky also received a novelization. Other manga, such as The Legend of Heroes: Trails from Zero Pre-Story -The Ring of Judgment- and Trails in the Sky Gaiden: The Tale of Loewe, are original works that provide backstory to certain characters.
=== Dairy and eggs === One of the main differences between a vegan and a lacto-ovo vegetarian diet is the avoidance of both eggs and dairy products such as milk, cheese, butter and yogurt. Ethical vegans do not consume dairy or eggs because they state that their production causes the animal suffering or a premature death. To produce milk from dairy cattle, farmers separate calves from their mothers soon after birth to retain cow milk for human consumption.
Sources: en.wikipedia.org
Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.
Dry powder is markedly more stable than solution and is usually held frozen and desiccated. Room temperature exposure over days degrades it more slowly than most people assume, but long-term integrity favors freezer storage. Light protection is recommended regardless of temperature.
Methods, columns, gradients, and detection wavelengths are not standardized across laboratories. Some figures describe only the main peak area at one wavelength and ignore water, salts, or counter-ions. Without stated conditions, comparing reported percentages across sources is unreliable.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.